Study Comparing Muraglitazar With Glimepiride in Type 2 Diabetics Who Are Not Controlled With Metformin Alone

Phase 3 Completed 1752 enrolled Bristol-Myers Squibb Merck Sharp & Dohme LLC · collab

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this clinical research study is to learn whether a muraglitazar-metformin combination is at least as effective as a glimepiride-metformin combination to treat type 2 diabetics who are not sufficiently controlled with metformin alone. The safety of this treatment will also be studied.

Timeline

Start: 2004-02
Primary completion: 2006-03
Completion: 2006-03

Outcome

Met primary endpoint

paper the reduction in HbA1C with muraglitazar 5 mg plus metformin was superior (p<0.0001) PMID 18777489 ↗

paper with muraglitazar 2.5 mg it was non-inferior in comparison with glimepiride PMID 18777489 ↗

Publications

Rubin CJ, Ledeine JM, Fiedorek FT. Improvement of glycaemic and lipid profiles with muraglitazar plus metformin in patients with type 2 diabetes: an active-control trial with glimepiride. Diab Vasc Dis Res. 2008 Sep;5(3):168-76. doi: 10.3132/dvdr.2008.028.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Muraglitazar	Small molecule	2.5 mg	—
Subject	Muraglitazar	Small molecule	5 mg	—